IgA Nephropathy Pipeline Analysis, 2017 - Clinical Trials & Results, Collaboration and Other Developments

The study analyzed that the IgA nephropathy pipeline comprises of 12 drug candidates, of which one drug candidate is in Phase III stage, five drug candidates are in Phase II stage and three drug candidates are in Pre-Clinical stage. Also, there are two inactive drug candidates and one discontinued drug candidate. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood. IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria and hematuria. IgA nephropathy does not have a specific treatment, and the only treatment available is to delay or prevent end stage renal disease (ESRD). Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis

As per the findings of the research, around 33.0% of drug candidates of IgA nephropathy pipeline are being developed to be administered by subcutaneous route and 22.0% are being developed to be administered by oral route. Route of administration of around 45.0% drug candidates of IgA nephropathy pipeline is not disclosed.

Many companies are involved in the development of IgA nephropathy pipeline, with their products in different phases. Mallinckrodt plc has its drug candidate in Phase III stage of development. Merck KGaA, Pharmalink AB, Anthera Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc. and Omeros Corporation each have their drug candidates in Phase II stage of development.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc., Pharmalink AB, Rigel Pharmaceuticals, Inc., Omeros Corporation, IGAN Biosciences, Inc., Shire plc and Visterra, Inc.